PL1664769T3 - Testy do wykrywania prohormonów przedsionkowego i mózgowego peptydu natriuretycznego - Google Patents

Testy do wykrywania prohormonów przedsionkowego i mózgowego peptydu natriuretycznego

Info

Publication number
PL1664769T3
PL1664769T3 PL04740371T PL04740371T PL1664769T3 PL 1664769 T3 PL1664769 T3 PL 1664769T3 PL 04740371 T PL04740371 T PL 04740371T PL 04740371 T PL04740371 T PL 04740371T PL 1664769 T3 PL1664769 T3 PL 1664769T3
Authority
PL
Poland
Prior art keywords
natriuretic peptide
brain natriuretic
assay
detecting atrial
peptide prohormones
Prior art date
Application number
PL04740371T
Other languages
English (en)
Inventor
Olli Vuolteenaho
Minna Ala-Kopsala
Heikki Ruskoaho
Juhani Leppäluoto
Jouko Haapalahti
Original Assignee
Orion Diagnostica Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Diagnostica Oy filed Critical Orion Diagnostica Oy
Publication of PL1664769T3 publication Critical patent/PL1664769T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
PL04740371T 2003-06-30 2004-06-28 Testy do wykrywania prohormonów przedsionkowego i mózgowego peptydu natriuretycznego PL1664769T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0315291A GB2403533A (en) 2003-06-30 2003-06-30 Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
EP04740371A EP1664769B1 (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones
PCT/EP2004/006971 WO2005003764A2 (en) 2003-06-30 2004-06-28 Assay for detecting atrial and brain natriuretic peptide prohormones

Publications (1)

Publication Number Publication Date
PL1664769T3 true PL1664769T3 (pl) 2012-06-29

Family

ID=27676371

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04740371T PL1664769T3 (pl) 2003-06-30 2004-06-28 Testy do wykrywania prohormonów przedsionkowego i mózgowego peptydu natriuretycznego

Country Status (14)

Country Link
US (3) US8283123B2 (pl)
EP (1) EP1664769B1 (pl)
JP (1) JP4741485B2 (pl)
AT (1) ATE538389T1 (pl)
AU (1) AU2004254028B2 (pl)
CA (1) CA2530623C (pl)
DK (1) DK1664769T3 (pl)
ES (1) ES2377122T3 (pl)
GB (1) GB2403533A (pl)
NO (1) NO339026B1 (pl)
PL (1) PL1664769T3 (pl)
PT (1) PT1664769E (pl)
SI (1) SI1664769T1 (pl)
WO (1) WO2005003764A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
WO2007003594A1 (en) * 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
JP5309026B2 (ja) 2006-08-04 2013-10-09 メディツィニッシュ ホホシュール ハノーバー Ｇｄｆ−１５に基づく心臓インターベンションの危険性を評価するための手段および方法
DE602006010705D1 (de) 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemische Marker für akute Lungenembolie
EP2180322A1 (en) 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Prognostic biomarkers for the progression of primary chronic kidney disease
CA2745288A1 (en) 2008-12-03 2010-06-10 Alisa Kabcenell Antibodies for guanylyl cyclase receptors
WO2010128071A1 (en) * 2009-05-05 2010-11-11 Brahms Ag Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction
JP5362487B2 (ja) * 2009-08-27 2013-12-11 塩野義製薬株式会社 ｐｒｏＢＮＰ−１０８の新規用途
WO2012019237A1 (en) 2010-08-12 2012-02-16 Madeleine Pharmaceuticals Pty Ltd Therapeutic method for treating congestive heart failure
EP2666475B1 (en) * 2011-01-21 2017-08-16 Igisu Co., Ltd. Therapeutic agent for alopecia
WO2014138796A1 (en) * 2013-03-15 2014-09-18 Madeleine Pharmaceuticals Pty Ltd Dosage regimen for therapeutic method
EP3116528A4 (en) 2014-03-14 2017-11-29 Madeleine Pharmaceuticals Pty Ltd Adjuvant therapy to standard of care (soc) diuretic treatment
US20170269067A1 (en) * 2016-03-17 2017-09-21 Charles L. GINSBURGH Use of fusion proteins to improve the availability of antigenic peptide epitopes in immunoassays
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid
GB2621544A (en) * 2022-07-07 2024-02-21 Biohabit Ltd Methods of detecting a disease or condition
CN117285624B (zh) * 2023-09-28 2024-04-26 北京达成生物科技有限公司 抗犬NT-proBNP双特异性抗体及试剂盒

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212286A (en) * 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
AU7481087A (en) 1986-05-09 1987-12-01 Biotechnoloty Research Associates J.V. Atrial natriuretic peptide receptor protein and its encoding dna
JPS6461500A (en) * 1987-09-01 1989-03-08 Shionogi & Co Alpha-hanp recognizing monoclonal antibody and immunologically measuring reagent for alpha-hanp
JPH0667319B2 (ja) 1989-04-19 1994-08-31 塩野義製薬株式会社 Ａｎｐのｃ端側を認識するモノクローナル抗体
DE69032598T2 (de) 1989-06-23 1999-03-11 Genentech, Inc., South San Francisco, Calif. Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
JP2665850B2 (ja) * 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
CA2188143A1 (en) 1992-12-09 1995-11-02 Wolf-Georg Forssmann Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof
WO1997032900A1 (en) 1996-03-04 1997-09-12 Scios Inc. ASSAY AND REAGENTS FOR QUANTIFYING hBNP
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6833358B1 (en) 1998-09-28 2004-12-21 Santen Pharmaceutical Co., Ltd. Lacrimal secretion promoters or eye drops for treating keratoconjunctival failure containing as the active ingredient natriuretic peptides
AT407674B (de) 1998-09-29 2001-05-25 Biomedica Gmbh Verfahren zur bestimmung von atrialem natriuretischem peptid (anp)
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
ES2292426T3 (es) 1999-01-29 2008-03-16 Roche Diagnostics Gmbh Metodo para detectar probnp n-terminal.
CA2364471A1 (en) * 1999-03-01 2000-09-08 Human Genome Sciences, Inc. Human serpin proteins
AU5043900A (en) * 1999-05-24 2000-12-12 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP2001349891A (ja) * 2000-04-03 2001-12-21 Unilever Nv 検査方法及びデバイス
WO2001079231A2 (en) * 2000-04-14 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the npr1 gene
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
US6461828B1 (en) 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
EP1451348B1 (en) * 2001-09-10 2015-08-12 Meso Scale Technologies, LLC Methods, reagents, kits and apparatus for protein function analysis
EP1461616A4 (en) * 2001-11-27 2005-08-10 Diagenics Internat Corp IMMUNOLOGICAL ASSAY AND KIT FOR EARLY AND SIMULTANEOUS DETECTION OF BIOCHEMICAL MARKERS IN THE SAMPLE OF A PATIENT
ATE272214T1 (de) * 2001-12-04 2004-08-15 Brahms Ag Verfahren zur diagnose von sepsis unter bestimmung von s100b
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP1616181B1 (en) * 2003-04-17 2009-08-12 Vermillion, Inc. Polypeptides related to natriuretic peptides and methods of their identification and use

Also Published As

Publication number Publication date
SI1664769T1 (sl) 2012-04-30
WO2005003764A3 (en) 2006-12-14
GB2403533A (en) 2005-01-05
US20130157311A1 (en) 2013-06-20
US20070141634A1 (en) 2007-06-21
PT1664769E (pt) 2012-03-09
US20160084852A1 (en) 2016-03-24
ATE538389T1 (de) 2012-01-15
CA2530623A1 (en) 2005-01-13
US8283123B2 (en) 2012-10-09
CA2530623C (en) 2014-09-16
US9151766B2 (en) 2015-10-06
JP2007526988A (ja) 2007-09-20
NO339026B1 (no) 2016-11-07
DK1664769T3 (da) 2012-03-19
EP1664769A2 (en) 2006-06-07
JP4741485B2 (ja) 2011-08-03
WO2005003764A2 (en) 2005-01-13
AU2004254028A1 (en) 2005-01-13
NO20060481L (no) 2006-01-30
AU2004254028B2 (en) 2010-10-14
ES2377122T3 (es) 2012-03-22
EP1664769B1 (en) 2011-12-21
GB0315291D0 (en) 2003-08-06

Similar Documents

Publication Publication Date Title
SI1664769T1 (sl) Preizkus za detektiranje atrijskih in moĹľganskih natriuretskih peptidnih prohormonov
WO2007131031A3 (en) Diagnosis of pulmonary and/or cardiovascular disease
AU2003288027A8 (en) Scd40l, papp-a and placental growth factor (plgf) used as a biochemical marker combination in cardiovascular diseases
WO1998030590A3 (en) Analogs of parathyroid hormone
WO2003026691A3 (en) Use of hmgb1 for the activation of dendritic cells
WO2000022439A3 (de) Verfahren und substanzen für die diagnose und therapie von sepsis und sepsisähnlichen systemischen infektionen
NZ510873A (en) Characterising polypeptides through cleavage and mass spectrometry
EP1183390B8 (en) METHODS FOR PREDICTING PREGNANCY OUTCOME IN A SUBJECT BY hCG ASSAY
WO2008125733A8 (en) Immunoassay for quantification of an unstable antigen selected from bnp and probnp
AU2003252111A8 (en) Fluorescent proteins, nucleic acids encoding them and methods for making and using them
WO2005116660A3 (en) Methods for making and using mass tag standards for quantitative proteomics
WO2009086125A3 (en) Affinity tag nucleic acid and protein compositions, and processes for using same
EP1652918A3 (en) Methods for detecting protein interactions using conformationally constrained peptides
WO2004055041A3 (en) Defensin-inducing peptides from fusobacterium
WO2006002841A3 (en) Analysis method
WO2005017237A3 (en) Apparatus and method for the selective assembly of protein
WO2008041849A3 (en) Methods and means for determining satiety on saliva
WO2009138466A3 (en) Novel polypeptides related to b-type natriuretic peptides and methods of their identification and use
WO2004070389A8 (en) Assay for protein isoforms
WO2006097564A8 (es) Nueva proteina epcr soluble de origen no proteolitico y su uso
AU3118300A (en) Cartilage resorption assays
WO2005114217A3 (en) Na+ and ci> coupled transport system for endogenous opioid peptides
WO2004060309A3 (en) Methods of treating and/or preventing autoimmune diseases
HUP0002557A3 (en) Simple quantitative fluorescent assay method for determining the activity of transport proteins of interest
WO2003062448A3 (en) Sqv nucleic acids and polypeptides